General Information
Drug ID
DR00175
Drug Name
Zalcitabine
Synonyms
1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; 2',3'-DIDEOXYCYTIDINE; 2',3'-Dideoxycytidine & Interferon-alpha; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); 2,3-dideoxycytidine; 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Beta-D-2',3'-Dideoxycytidine; Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Beta-D-DDC; Cytidine, 2',3'-dideoxy & Interferon alpha; Cytidine, 2',3'-dideoxy-& Colony-stimulating factor; D 5782; DDC (DDC); DS-4152 & ddC; DdC; DdC & GM-CSF; DdC & IFN-alpha; DdC & Interferon alpha; DdC & NP (from PHCA or HSA); DdC & sCD4; DdC (Antiviral); DdCyd; Dideoxycytidine; HIVID; Hivid (TN); Hivid(TM); Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; Interferon AD + ddC; KS-1130; Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine; PC-SOD & ddC; Ro 24-2027/000; Ro-24-2027/000; SRI-7707; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Zalcitabine (JAN/USP/INN); Zalcitabine [USAN:INN:BAN]; Zalcitibine
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD11: 1C62.Z] Approved [1]
Therapeutic Class
Anti-HIV Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=24066"></iframe>
3D MOL 2D MOL
Formula
C9H13N3O3
Canonical SMILES
C1CC(OC1CO)N2C=CC(=NC2=O)N
InChI
InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
InChIKey
WREGKURFCTUGRC-POYBYMJQSA-N
CAS Number
CAS 7481-89-2
Pharmaceutical Properties Molecular Weight 211.221 Topological Polar Surface Area 88.2
Heavy Atom Count 15 Rotatable Bond Count 2
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
XLogP
-1.3
PubChem CID
24066
PubChem SID
11467065 , 11468185 , 11486840 , 11504751 , 11528334 , 11532889 , 14797711 , 15171927 , 17389522 , 17404923 , 22391526 , 22431601 , 24278377 , 24862834 , 25819962 , 26719633 , 26752752 , 26752753 , 29291163 , 3259589 , 46386814 , 46488030 , 46507879 , 47216920 , 47216921 , 47589142 , 48185139 , 48334652 , 48416706 , 48422195 , 48422429 , 48423540 , 48424478 , 49681781 , 49693297 , 49699414 , 49734166 , 50105404 , 50105405 , 595891 , 596441 , 596607 , 596679 , 601537 , 602107 , 7847478 , 7980904 , 8167576 , 878108 , 9416
ChEBI ID
CHEBI:10101
TTD Drug ID
D0Z9QR
DT(s) Transporting This Drug MRP8 Transporter Info Multidrug resistance-associated protein 8 Substrate [2]
OAT1 Transporter Info Organic anion transporter 1 Substrate [3]
References
1 Zalcitabine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. J Biol Chem. 2003 Aug 8;278(32):29509-14.
3 Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.